GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 204 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 1.05 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $31,841,000 | -67.7% | 467,573 | -84.8% | 0.00% | -70.0% |
| Q2 2022 | $98,461,000 | -30.5% | 3,081,717 | -24.7% | 0.01% | -9.1% |
| Q1 2022 | $141,735,000 | +13.1% | 4,091,699 | -4.5% | 0.01% | +22.2% |
| Q4 2021 | $125,347,000 | +63.7% | 4,282,401 | +42.5% | 0.01% | +50.0% |
| Q3 2021 | $76,594,000 | +51.4% | 3,006,051 | +108.0% | 0.01% | +50.0% |
| Q2 2021 | $50,602,000 | -57.3% | 1,444,957 | -50.4% | 0.00% | -60.0% |
| Q1 2021 | $118,622,000 | -37.9% | 2,910,964 | -33.9% | 0.01% | -41.2% |
| Q4 2020 | $190,870,000 | -48.0% | 4,407,065 | -33.8% | 0.02% | -54.1% |
| Q3 2020 | $367,243,000 | -36.4% | 6,660,208 | -27.1% | 0.04% | -41.3% |
| Q2 2020 | $577,038,000 | +35.0% | 9,140,454 | +9.2% | 0.06% | +6.8% |
| Q1 2020 | $427,532,000 | +2.7% | 8,368,206 | +59.8% | 0.06% | +28.3% |
| Q4 2019 | $416,237,000 | +40.8% | 5,236,355 | -14.0% | 0.05% | +31.4% |
| Q3 2019 | $295,588,000 | -29.1% | 6,092,069 | -23.1% | 0.04% | -28.6% |
| Q2 2019 | $416,854,000 | -6.4% | 7,924,985 | -5.9% | 0.05% | -7.5% |
| Q1 2019 | $445,549,000 | +30.3% | 8,417,709 | +1.1% | 0.05% | +12.8% |
| Q4 2018 | $341,921,000 | +15.2% | 8,329,399 | +6.7% | 0.05% | +42.4% |
| Q3 2018 | $296,698,000 | +1.8% | 7,807,836 | +21.0% | 0.03% | -2.9% |
| Q2 2018 | $291,549,000 | -16.4% | 6,450,194 | -10.6% | 0.03% | -17.1% |
| Q1 2018 | $348,607,000 | +58.7% | 7,217,539 | +29.3% | 0.04% | +57.7% |
| Q4 2017 | $219,733,000 | +35.4% | 5,584,053 | +6.8% | 0.03% | +30.0% |
| Q3 2017 | $162,297,000 | +10.1% | 5,226,931 | -3.1% | 0.02% | +11.1% |
| Q2 2017 | $147,461,000 | -30.5% | 5,391,650 | -6.4% | 0.02% | -33.3% |
| Q1 2017 | $212,236,000 | +162.4% | 5,759,471 | +2.9% | 0.03% | +145.5% |
| Q4 2016 | $80,883,000 | -37.3% | 5,597,467 | +0.1% | 0.01% | -35.3% |
| Q3 2016 | $128,914,000 | +40.4% | 5,592,811 | +1.1% | 0.02% | +30.8% |
| Q2 2016 | $91,800,000 | +26.5% | 5,533,461 | +21.0% | 0.01% | +30.0% |
| Q1 2016 | $72,549,000 | -50.9% | 4,574,292 | +0.1% | 0.01% | -50.0% |
| Q4 2015 | $147,701,000 | -20.6% | 4,568,562 | +3.5% | 0.02% | -23.1% |
| Q3 2015 | $186,112,000 | – | 4,414,433 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |